|
1
|
Lee YJ, Kim JH, Kim SK, et al: Lung cancer
in never smokers: change of a mindset in the molecular era. Lung
Cancer. 72:9–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wong DW, Leung EL, So KK, et al: The
EML4-ALK fusion gene is involved in various histologic types of
lung cancers from non smokers with wild-type EGFR and KRAS. Cancer.
115:1723–1733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaw AT, Yeap BY, Solomon BJ, et al:
Effect of crizotinib on overall survival in patients with advanced
non-small-cell lung cancer harbouring ALK gene rearrangement: a
retrospective analysis. Lancet Oncol. 12:1004–1012. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ju YS, Lee WC, Shin JY, et al: Fusion of
KIF5B and RET transforming gene in lung adenocarcinoma revealed
from whole-genome and transcriptome sequencing. Genome Res.
22:436–445. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lipson D, Capelletti M, Yelensky R, et al:
Identification of new ALK and RET gene fusions from colorectal and
lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kohno T, Ichikawa H, Totoki Y, et al:
KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takeuchi K, Soda M, Togashi Y, et al: RET,
ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sasaki H, Endo H, Konishi A, et al: EGFR
mutation status in Japanese lung cancer patients: genotyping
analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sasaki H, Shimizu S, Endo K, et al: EGFR
and erbB2 mutation status in Japanese lung cancer patients. Int J
Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sasaki H, Hikosaka Y, Kawano O, Moriyama
S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number
gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki H, Okuda K, Kawano O, et al: Nras
and Kras mutation in Japanese lung cancer patients: genotyping
analysis using LightCycler. Oncol Rep. 18:623–628. 2007.PubMed/NCBI
|
|
15
|
Sasaki H, Kawano O, Endo K, et al:
Uncommon V599E Braf mutations in Japanese patients with lung
cancer. J Surg Res. 133:203–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grieco M, Santoro M, Berlingieri MT, et
al: PTC is a novel rearranged form of the ret proto-oncogene and is
frequently detected in vivo in human thyroid papillary carcinomas.
Cell. 60:557–563. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alberti L, Carniti C, Miranda C, Roccato E
and Pierotti MA: RET and NTRK1 proto-oncogenes in human diseases. J
Cell Physiol. 195:168–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeng Q, Cheng Y, Zhu Q, et al: The
relationship between overexpression of glial cell-derived
neurotrophic factor and its RET receptor with progression and
prognosis of human pancreatic cancer. J Int Med Res. 36:656–664.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dawson DM, Lawrence EG, MacLennan GT, et
al: Altered expression of RET proto-oncogene product in prostatic
intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst.
90:519–523. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohshima Y, Yajima I, Takeda K, Kumasaka M,
Matsumoto M and Kato M: c-RET molecule in malignant melanoma from
oncogenic RET-carrying transgenic mice and human cell lines. PLoS
One. 5:e102792010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanizaki J, Okamoto I, Sakai K and
Nakagawa K: Differential roles of trans-phosphorylated EGFR, HER2,
HER3, and RET as heterodimerisation partners of MET in lung cancer
with MET amplification. Br J Cancer. 105:807–813. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Henderson YC, Ahn SH, Kang Y and Clayman
GL: Sorafenib potently inhibits papillary thyroid carcinomas
harboring RET/PTC1 rearrangement. Clin Cancer Res. 14:4908–4914.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carlomagno F, Anaganti S, Guida T, et al:
BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer
Inst. 98:326–334. 2006.
|
|
24
|
Kim DW, Jo YS, Jung HS, et al: An orally
administered multitarget tyrosine kinase inhibitor, SU11248, is a
novel potent inhibitor of thyroid oncogenic RET/papillary thyroid
cancer kinases. J Clin Endocrinol Metab. 91:4070–4076. 2006.
View Article : Google Scholar
|
|
25
|
Dawson S, Conus NM, Toner GC, Raleigh JM,
Hicks RJ, McArthur G and Rischin D: Sustained clinical responses to
tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Anticancer Drugs. 19:547–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takeuchi K, Choi YL, Togashi Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Score J, Curtis C, Waghorn K, et al:
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion
gene following screening for PDGFRA overexpression in patients with
hypereosinophilia. Leukemia. 20:827–832. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahashi T, Sonobe M, Kobayashi M, et al:
Clinicopathologic features of non-small-cell lung cancer with
EML4-ALK fusion gene. Ann Surg Oncol. 17:889–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Inamura K, Takeuchi K, Togashi Y, et al:
EML4-ALK fusion is linked to histological characteristics in a
subset of lung cancers. J Thorac Oncol. 3:13–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inamura K, Takeuchi K, Togashi Y, et al:
EML4-ALK lung cancers are characterized by rare other mutations, a
TTF-1 cell lineage, an acinar histology, and young onset. Mod
Pathol. 22:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida A, Tsuta K, Nakamura H, et al:
Comprehensive histologic analysis of ALK-rearranged lung
carcinomas. Am J Surg Pathol. 35:1226–1234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Camidge DR, Kono SA, Lu X, et al:
Anaplastic lymphoma kinase gene rearrangements in non-small cell
lung cancer are associated with prolonged progression-free survival
on pemetrexed. J Thorac Oncol. 6:774–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang P, Kulig K, Boland JM, et al: Worse
disease-free survival in never-smokers with ALK+ lung
adenocarcinoma. J Thorac Oncol. 7:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu SG, Kuo YW, Chang YL, et al: EML4-ALK
translocation predicts better outcome in lung adenocarcinoma
patients with wild-type EGFR. J Thorac Oncol. 7:98–104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
